CLOSED
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. Track Granules India Limited's live NSE:GRANULES share price ₹845.10 (+2.50%), market cap ₹₹209B, P/E 31.3. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for GRANULES — real-time NSE India stock intelligence.
Open
₹827.80
High
₹848.65
Low
₹814.20
Prev. Close
₹824.50
52W High
₹910.00
52W Low
₹432.60
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives.
Key Takeaway
Granules India Limited is rated strong buy with a P/E of 31.3x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Granules India Limited fairly valued right now?
Because a P/E of 31.3x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Granules India Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
1,465 Cr
Revenue
180 Cr
Net Profit
0%
ROE
0%
ROCE
26.97
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 4,496 | 4,490 | 4,456 | 5,339 | 5,595 |
| Net Profit | 517 | 405 | 502 | 595 | 663 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 26.97 | 26.97 |
| Debt/Equity | — | — | — | 29.7 | 29.7 |